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ABSTRACT 
Systemic lupus erythematosis (SLE), scleroderma, myositis and Sjӧgren's sydrome (SS) are 
rare, complex, multi-systemic rheumatic diseases associated with significant morbidity and 
mortality. Thorough assessments of disease activity are required to guide clinical 
management and assess response to new therapies in clinical trials.  In this article, we shall 
review the commonly used outcome measures to assess this group of diseases and discuss 
the limitations of their use.  
INTRODUCTION 
Outcome measures form a crucial component of clinical practice and research. A 
standardised assessment of disease activity provides an accurate trend of disease activity 
overtime and prompts changes in patient’s management. Over the last decade, there has 
been burgeoning research into the pathogenesis of SLE, scleroderma, autoimmune 
myopathies and SS, leading to the development of novel therapeutic targets. Robust 
measures of disease activity are required to accurately assess the efficacy of these new 
therapies in clinical trials. The Outcomes Measures in Rheumatologic Trials group 
(OMERACT) (Tugwell et al., 2007) have established clear constructs for outcome measures; 
stating that they should be valid, sensitive, reproducible, sensitive to change and feasible.  
In this article, we shall review the common outcome measures used to assess this group of 
diseases and the limitations of their use.   
  
Systemic lupus erythematosus (SLE) 
SLE is a chronic multisystem autoimmune disease with a heterogeneous pattern of clinical 
and serological manifestations. Pathogenesis of the disease involves a complex interaction 
between gene susceptibility, hormonal influences and certain environmental triggers which 
induce autoantibody production (Rahman and Isenberg, 2008). It has an overall incidence of 
4.9-5.5 and prevalence of 72.8-97 in recent UK and US population estimates with a 6-10 fold 
female predominance (Somers et al., 2014) .  
Several tools have been developed to assess disease activity both in clinical practice and as 
primary endpoints in clinical trials. The primary tools used are the BILAG-2004 developed 
and validated by the British Isles Lupus Assessment Group (Romero-Diaz, Isenberg and 
Ramsey-Goldman, 2011), SLEADI-2K (systemic lupus erythematosus disease activity index 
2000) (Gladman et al., 2003) and SLICC (systemic lupus international collaborating clinics) 
(Gladman et al., 1996). Limitations of individual disease activity scores lead to the 
development of composite indices such as SLE responder index (SRI and SRI-50) (Mikdashi 
and Nived, 2015) (Castrejon et al., 2014) and the BILAG based composite lupus assessment 
(BLICA) (Castrejon et al., 2014). The most commonly used patient reported outcome score is 
the Lupus Quality of Life Questionnaire (Lupus-QoL) (Holloway et al., 2014).  
 
 
 
 
 
 
Figure 1: Outcome measures in SLE  
Disease activity scores 
British Isles Lupus Assessment Group Index (BILAG-2004) (Romero-Diaz, Isenberg and Ramsey-
Goldman, 2011) 
 Nine systems are measured: constitutional, mucocutaneous, neuropsychiatric, 
musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and haematological 
 Features graded as new, the same, worse or improving.  
 Incorporates severity and provides assessment scales for individual organs and systems  
 Accurate scoring requires that the physician only counts activity that is attributable to lupus 
 Activity in each organ system is scored as: A = most active disease (12 points); B = 
intermediate activity (8 points); C = mild, stable disease (1 point); D = previous involvement, 
currently inactive (0 points); E = no previous activity (0 points). Flares can also be assessed 
with a severe flare = A; new appearance and moderate flare = B; and recurrence as score of D 
or E 
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEADI-2K) (Gladman et al., 2003) 
 Global index of disease activity in SLE 
 Consists of 24 questions  
 Records descriptors of disease activity as present or absent in the preceding 10 or  30 days 
along with persistent rash, alopecia, oral ulcers and proteinuria limiting its use in clinical trials  
 Measures disease activity in 9 organ systems: neurological, musculoskeletal, renal, 
mucocutaneous, general, cardiac, respiratory, vascular, and hematological with a scoring 
range of 1-8 
 Provides a single summary score for disease activity with a maximum score of 105 
SLE responder index (SRI) (Castrejon et al., 2014) 
 Combination index of SELENA-SLEDAI, BILAG and physician global assessment  
 A responder is classified as SELENA-SLEDIA improvement of 4 or more points from baseline 
 No new BILAG A or B scores 
 No worsening of physician global assessment  
SLEDAI-2000 Responder Index 50 (SRI 50)  (Mikdashi and Nived, 2015) 
 Composed of SLEDAI-2K and generates a numerical score that reflects disease activity over the 
previous 30 days  
 Each descriptor identifies at least a 50% improvement which generates a score for that 
descriptor  
BILAG-Based Composite Lupus Assessment (BICLA) (Castrejon et al., 2014) 
 Combination of BILAG, PGA and SLEADI 
 Responder classified as no new BILAG A or B scores 
 Improvement of BLAG A score to B, BILAG B/C/D to BILAG C/D 
 No increase in SLEDAI from baseline 
 No worsening of PGA 
Damage indices 
Systemic Lupus International Collaborating Clinics Damage Index (SLICC) (Gladman et al., 1996) 
 Damage assessment index  
 Includes 42 items in 12 domains with a maximum score of 46. Items are rated as being either 
present or absent with recurring events being scored either 2 or 3. 
 Irreversible damage is defined as change in an organ or system that has occurred since the onset 
of disease and has been present ≥6 months  
Patient reported outcomes  
Lupus Quality of Life Questionnaire (LupusQoL) (Holloway et al., 2014) 
 Patient reported quality of life questionnaire  
 34 questions covering the preceding four weeks  
 Five-point scale ranging from “never” to “all of the time” 
Scleroderma 
Scleroderma, also known as systemic sclerosis, is a rare autoimmune disease associated 
with significant morbidity and mortality. It is characterised by vascular injury and abnormal 
fibrotic processes that can affect multiple organ systems, including the skin, lungs, 
gastrointestinal (GI) tract and cardiovascular system.  
Skin involvement in scleroderma is almost universal. The modified Rodnan skin score (mRSS) 
(Clements et al., 1995) is a validated measure of skin disease and has become the most 
commonly used measure of disease activity in patients with systemic sclerosis. The mRSS 
correlates with patient derived measures of disease, physical function and mortality. 
However, there is a high inter-observer variation in this score. Disease of the GI system 
occurs in approximately 90% of patients with scleroderma and has a major impact on their 
health-related quality of life. However, few instruments have been validated for the 
assessment of GI tract in scleroderma. Interstitial lung disease and pulmonary arterial 
hypertension are the leading cause of death in patients with scleroderma. Lung function 
tests and the 6 minute walk test are surrogate markers for these disease parameters in 
clinical trials. The 6 minute walk test measures the distance a patient can walk in six minutes 
and has been successfully incorporated into trials of scleroderma-related PAH (Badesch et 
al., 2000). Raynaud’s phenomenon (RP) occurs in more than 90% of patients with 
scleroderma and is measured using the RP score (Merkel et al., 2002). Severe Raynaud’s can 
lead to digital ulcers (DU). These are manually counted to provide a DU score. The HAQ I is a 
widely used patient reported outcome score used in rheumatic diseases (Fries et al., 1980) 
and has been validated in scleroderma.  The scleroderma HAQ is a variation of the HAQ 
incorporating questions specific to scleroderma disease (Steen and Medsger, 1997).  
 
Figure 2: Outcome measures in scleroderma 
Disease activity scores 
Modified Rodnan skin score (mRSS) (Clements et al., 1995) 
Skin thickness across 17 regions of the body. Clinician uses index finger and thumb to roll or gently pinch 
skin. A scale 0-3 is applied. 0-No thickening, 1-Mild thickening, 2-Moderate thickening, 3-Severe thickening  
Pulmonary function tests  
Vital capacity (VC), Forced vital capacity and Diffusing capacity for carbon monoxide are important variables 
in the assessment of lung involvement 
6 minute walk test 
The 6-minute walk test (6MWT) measures the distance a person can walk in 6 minutes  
Raynaud’s condition score (Merkel et al., 2002) 
The RCS is calculated from a summation of 1- or 2-week daily patient self-assessments of RP activity using a 
0 to 10 ordinal scale. The RCS incorporates the cumulative daily frequency, duration, severity, and impact of 
RP attacks.  
Digital ulceration count 
Manual count of the number of digital ulcers 
Patient reported outcomes 
HAQ-DI (Fries et al., 1980) 
The HAQ-DI assesses eight disability categories over the past 7 days (dressing/grooming, arising, eating, 
walking, hygiene, reach, grip, common daily activities). Items are rated on a 4-point scale, ranging from 0 
(without any difficulty) to 3 (unable to do), with higher scores indicating greater functional disability. The 
total score is the mean of the highest scores of each of the eight categories, ranging from 0 (no disability) to 
3 (severe disability).  
The Scleroderma HAQ (SHAQ) (Steen and Medsger, 1997) 
Includes the disability and pain scales of the HAQ plus five visual analogue scales (VASs) that patients use to 
rate scleroderma-specific problems in the preceding week including pulmonary disease, digital ulcers, 
Raynaud’s phenomenon, GI disease, and skin disease 
 
Inflammatory myopathies 
The idiopathic inflammatory myopathies (IIM) are characterised by auto immune mediated 
muscle inflammation and weakness. They have a worldwide prevalence of 14 in 100,000 
(Meyer et al., 2015). Adult polymyositis (PM), dermatomyositis (DM), and juvenile 
dermatomyositis (JDM) are among the most frequent of the IIM. During the past decade, 
collaborations such as the International Myositis Assessment & Clinical Studies Group 
(IMACS) have undertaken projects to define core measures of disease activity and damage 
in myositis and dermatomyositis, and to develop and validate tools for these measures 
(Isenberg et al., 2004). 
 
The most commonly-used tools include the Manual Muscle Test 8 (MMT8) (Miller et al., 
2001); Myositis Intention to Treat (MITAX); and Myositis Disease Activity Assessment Tool 
(MYOACT) (Isenberg et al., 2004). Disease damage measures are used to assess the 
persistent change in anatomy, physiology, pathology or function resulting from previously 
active disease or complications of therapy. Usually, changes are post-inflammatory, 
cumulative and irreversible. Damage should be present for at least six months despite 
previous immunotherapy, rehabilitation or other therapy. The most commonly-used tool to 
assess disease damage is Myositis Damage Index (MDI) (Isenberg et al., 2004). 
 
In addition to measuring myositis-specific activity and damage, Rider and colleagues (2011) 
also recommend the use of the following tools: general tools of global disease activity (e.g.  
physician and patient visual analogue scales - VAS); functional assessment tools (e.g. Health 
Activity Questionnaire – HAQ, and childhood myositis assessment score); and patient-
reported outcome measures (e.g. health-related quality of life measures such as SF36 for 
adults or CHQ-PF50 for children). 
Figure 3: Outcomes measures in myositis  
Assessment of myositis activity   
Muscle assessment  
Manual Muscle Test 8 (MMT8, a modified, shorter version of MMT) 
 Part of the physical examination, requiring no specific equipment, to measure muscle strength. 
 A summary score assessing eight proximal, distal and axial muscles in the upper and lower 
extremities, using 0-10 point scale. Each muscle group tested is scored by using either the modified 
MRC or Kendall grading scale, depending on how much the muscle group can do in terms of 
moving against gravity or against applied pressure. 
 Partially validated, it is used internationally and in all subsets of myositis including adult and 
juvenile PM and DM, as well as for a number of neuromuscular conditions. 
 Extremely useful for long-term monitoring of myositis patients in both clinical and research 
settings. However, requires adequate training to perform and does not discriminate between 
activity and damage. (Rider et al 2011) 
Extra-muscular assessment: 
Myositis Intention to Treat (MITAX) 
 The MITAX assesses specific manifestations in seven organs or systems (constitutional, cutaneous, 
skeletal, gastrointestinal, pulmonary, cardiac, and muscle). Each clinical features is recorded using 
a scale of 0-4 (0 = not present; 1 = improving; 2 = the same; 3 = worse; 4 = new). The score is then 
converted using a scoring schema to an overall disease activity score for each system, which 
indicates the level of treatment needed.  
Myositis Disease Activity Assessment Tool (MYOACT)  
 Assesses severity of activity in each organ system with a 10-cm visual analogue scale (VAS), and a 
global extra-muscular VAS.  
Assessment of myositis damage 
Myositis Damage Index (MDI) 
 A comprehensive tool to assess the extent and severity of damage developing in 11 organs 
systems. A complete history and physical examination is needed, although minimal training 
required. 
 Organ-specific questions ask the presence or absence of a given sign or symptom, and the overall 
rating of disease damage in each system using 10cm visual analogue scale to measure severity.  
 The MDI can be used in both adult and juvenile PM and DM patients, although due to its 
comprehensive nature, may reflect damage caused by co-morbid conditions not just myositis. 
 
Dermatomyositis 
Myositis occurring with characteristic skin and nail manifestations is coined 
dermatomyositis (DM).  These manifestations may include Gottron's papules, helitrope rash, 
photo-distributed erythema, poikiloderma, dilated nail fold capillaries, scalp involvement 
and calcinosis cutis. The Cutaneous Dermatomyositis Disease Area and Severity Index 
(CDASI), is the most commonly used combined tool in clinical practice and therapeutic 
studies for DM (Klein et al., 2008). It is a clinician scored instrument that measures skin 
activity and damage. Activity is measured in three areas – erythema, scale, and 
erosion/ulceration. Damage is measured in two areas – poikiloderma and calcinosis. In 
addition, Gottrons papules, periungual changes and alopecia are also scored. 
Figure 4: Dermatomyositis-related rash  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5: Example of CDASI scoring of dermatomyositis rash 
 
 
Sjӧgren's sydrome  
Sjögren’s syndrome (SS) is a chronic autoimmune disorder affecting approximately 
0.1–0.4% of the general population with a female-to-male ratio of 9:1, usually diagnosed in 
the fourth and fifth decades of life (Daridon et al., 2007). Clinically, SS is characterised by 
ocular and oral dryness developed because of the autoimmune infiltrating process affecting 
the exocrine glands. It may occur either alone, as primary SS, or in association with other 
autoimmune disease, often rheumatoid arthritis, systemic lupus erythematosus or systemic 
sclerosis, in which case is called secondary SS. Clinical, laboratory and histological features 
can be used to classify the systemic manifestations of SS as periepithelial or tissue-specific 
(including liver, lung and kidney) and extraepithelial (including vasculitis, peripheral 
neuropathy, renal involvement and myositis) (Fox et al., 1984).  
 In the past decades, a core set of domains was defined to facilitate the complex 
assessment of SS patients’ outcomes (Seror et al., 2012). This included sicca symptoms, 
objective measurements of tear and saliva production, fatigue, quality of life, disease activity 
and damage indexes.  
Significant efforts have been made to develop valid tools for the assessment of various 
clinical and laboratory manifestation of SS, as the disease can have a heterogeneous 
presentation. A large international project supported by EULAR, led to the development of 
two consensus disease activity indexes: the EULAR Sjögren's Syndrome Patients Reported 
Index (ESSPRI) (Seror et al., 2011), and the EULAR Sjögren's Syndrome Disease Activity Index 
(ESSDAI) (Seror et al., 2015), a systemic activity index to assess systemic manifestations, which 
are the most used outcome measures in SS. In addition, patient questionnaires such as the 
Profile of Fatigue and Discomfort (PROFAD) and Sicca Symptoms Inventory (SSI) have also 
been developed. The table below details the most used disease specific outcome measures 
in SS.  
 
  
Figure 6: Outcomes measures in Sjӧgren's sydrome 
Disease activity scores 
Sjӧgren’s Clinical Activity Index (SCAI) (Bowman et al., 2007) 
 Originated from the BILAG 
 Consists of 42 questions from 8 domains (constitutional, musculoskeletal, cutaneous/vascular, 
respiratory, neurological, renal, salivary gland, haematological)  
 Scored as new, same, worse, improving or not present 
Sjӧgren’s Syndrome Disease Activity Index (SSDAI) (Vitali et al., 2007) 
 Assessment of disease activity 
 Eight domains: constitutional, salivary gland, articular, haematological, pleuro-pulmonary, vasculitis, 
renal, peripheral neuropathy 
 
EULAR Sjӧgren’s Syndrome Disease Activity Index (ESSDAI) (Seror et al., 2015) 
 Assessment tool of disease activity in pSS 
 Twelve Domains: constitutional, lymphadenopathy and lymphoma, glandular, articular, cutaneous, 
pulmonary, renal, muscular, peripheral nervous system, central nervous system, haematological, 
biological 
Damage indexes 
Sjӧgren’s Syndrome Disease Damage Index (SSDDI)  (Vitali et al., 2007)  
 Developed for the Italian cohort 
 Assessment of damage 
 Six domains: Oral/salivary damage, ocular damage, neurologic damage, pleuropulmonary, renal, 
lymphoproliferative 
Sjӧgren’s Syndrome Damage Index (SSDI) (Barry et al., 2008) 
 Developed for the UK cohort 
 Assessment of damage 
 Ten domains: Ocular, oral, neurological, renal, pulmonary, cardiovascular, gastrointestinal, 
musculoskeletal, endocrine, malignancy 
 
Patient reported outcomes 
EULAR Sjӧgren’s Syndrome Patient Reported Index (ESSPRI) (Seror et al., 2011) 
 Derived from PROFAD-SSI 
 Patient questionnaire to assess symptoms rather than disease activity as the ESSDAI 
 Three questions regarding dryness, fatigue, pain 
 Scale of 0-10 
 Reported to be an independent predictor of health-related quality of life in pSS patients (Cho et al., 
2013).  
 
PROFAD-SSI score (profile of fatigue and discomfort sicca symptoms inventory)   
 PROFAD-SSI score is a 64-point questionnaire that covers symptoms of somatic fatigue, mental 
fatigue, arthralgia, vascular symptoms, sicca (ocular and oral) symptoms, cutaneous and vaginal 
dryness 
 The PROFAD-SSI-SF (short form) score is a 19-point questionnaire abbreviated from the above which 
has been validated as a pSS outcome tool (Bowman et al., 2009) 
 Fatigue VAS was found to most closely correlate with somatic fatigue  
 The somatic fatigue domain forms the PROF-S whilst the mental fatigue domain forms the PROF-M 
(derived from patient’s descriptions of fatigue) 
 
  
The ESSDAI and ESSPRI scores are currently used as gold standard in clinical trials. An ESSDAI 
≥5 signifies moderately active disease, while a minimal clinically important improvement is 
defined as a decrease of at least 3 points (Seror et al., 2011). An ESSPRI score above 5 defines 
significant impact of SS associated symptoms on patients’ quality of life (Cho et al., 2013).  
Both ESSDAI and ESSPRI are found to be sensitive to change (Meiners et al., 2012) ; therefore 
they are the most used outcome measures in SS.  
Conclusions 
A number of outcome measures have been validated for the assessment of rare 
rheumatologic diseases.  The multi-systemic nature of these diseases pose a significant 
challenge to accurately capture the spectrum of disease activity and damage. Furthermore, 
the rarity of these diseases limits the power of validity and reproducibility assessments for 
outcome measures. As we advance our understanding of the pathogenesis of these 
diseases, and develop novel therapeutic targets, refinement of these outcome measures will 
become necessary.   
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